Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease
Table 2
Patient characteristics at baseline.
Study
Raju et al.
Deftereos et al.
LoDoCo
COLIN
LoDoCo-MI
COLCOT
LoDoCo-2
COPS
Colchicine
Placebo
Colchicine
Placebo
Colchicine
Placebo
Colchicine
Placebo
Colchicine
Control
Colchicine
Placebo
Colchicine
Placebo
Colchicine
Nonexposed
Number of patients
40
40
100
96
282
250
23
21
119
118
2366
2379
2762
2760
396
399
Mean age (y)
57.2
57.2
63.7
63.5
66
67
60.1
59.7
61
61
60.6
60.5
65.8
65.9
59.7
60.0
Male (%)
85
93
63
68
89
89
82.5
76.2
75
79
80.1
81.6
83.5
85.9
81
78
Diabetes (%)
18
15
100
100
33
28
13.0
14.3
23
21
19.5
20.9
17.8
18.7
19
19
Hypertension (%)
48
38
48
49
—
—
39.1
47.6
54
41
50.1
52
51.4
50.3
51
50
Smoker (%)
45
43
36
40
4
6
73.9
66.7
65
57
29.9
29.8
11.5
12.0
32
37
Medications (%) Aspirin
100
100
—
—
931
941
-2
-2
99
100
98.6
98.9
66.9
67.1
99
98
Statin
100
95
—
—
96
94
—
—
97
100
98.9
99.1
93.9
94.0
98
99
ACEI/ARB
—
—
—
—
55
60
—
—
96
92
—
—
72.2
71.2
88
86
Beta-blocker
—
—
—
—
62
71
—
—
93
92
89.4
88.3
61.3
62.9
81
85
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker. 1Aspirin and/or clopidogrel. 2As per authors, all patients received aspirin at the time of primary PCI, but the percentage of patients that remained on aspirin in each arm is not stated.